Drug Trial Radar · NCT00819234
Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin
Last checked: Nov 20, 2026Latest source record: Apr 15, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
274
Actual
Start
Nov 2008
Primary completion
Oct 2009
Study completion Nov 2009
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jan 8, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study DFA102E is an extension of Study DFA102, which included a 28-week treatment period with randomized study medication. The purpose of the extension study is to examine the long-term (up to 1 year) safety, tolerability, and effect on body weight of treatment with pramlintide and metreleptin, administered as separate subcutaneous (SC) injections, in obese and overweight subjects.
Conditions
- Obesity
Interventions
PlaceboDrug
placebo pramlintide and placebo metreleptin twice daily
Pramlintide and MetreleptinDrug
Subcutaneous injection, twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- LS Mean Percent Change in Body Weight From Original Study DFA102 (NCT00673387) Baseline (Day 1) at Week 52 in Extension Study DFA102E - Evaluable Treatment Stable PopulationTime frame: Original Study Baseline to Week 52
Locations
33 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Phoenix, Arkansas
Research Site
Santa Rosa, California
Research Site
Walnut Creek, California
Research Site
Denver, Colorado
Research Site
Jacksonville, Florida
Research Site
Miami, Florida
Research Site
Plantation, Florida
Research Site
Atlanta, Georgia
Research Site
Chicago, Illinois
Research Site
Springfield, Illinois
Research Site
Kansas City, Kansas
Research Site
Baton Rouge, Louisiana
Research Site
Boston, Massachusetts
Research Site
Edina, Minnesota
Research Site
St Louis, Missouri
Research Site
Butte, Montana
Research Site
New York, New York
Research Site
Cincinnati, Ohio
Research Site
Columbus, Ohio
Research Site
Eugene, Oregon
Research Site
Medford, Oregon
Research Site
Anderson, South Carolina
Research Site
Greer, South Carolina
Research Site
Mt. Pleasant, South Carolina
Research Site
Nashville, Tennessee
Research Site
Austin, Texas
Research Site
Dallas, Texas
Research Site
San Antonio, Texas
Research Site
Salt Lake City, Utah
Research Site
Norfolk, Virginia
Research Site
Bellingham, Washington
Research Site
Olympia, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.